CClinicalTrials.gg
Not yet recruitingNCT04596956Updated Oct 22, 2020

Safety and Efficacy of Sodium Bicarbonate Ringer Injection

A Phase 4 interventional study of sodium bicarbonate Ringer injection and Lactated Ringer's solution in Ringer Bicarbonate, Elderly Abdominal Surgery and Safety, sponsored by Chinese PLA General Hospital. Not yet recruiting. Open to participants aged 65 Years and older. Per ClinicalTrials.gov, last updated 2020-10-22.

Sponsored by Chinese PLA General Hospital · Phase 4, Interventional, and Treatment

From the registry’s dates

  • Primary completion was expected by Aug 2025, 1 year 2 months ago, but the record still lists the study as not yet recruiting.
Phase
Phase 4
Study type
Interventional
Enrollment
5,000
Allocation
Randomized
Ages
65 Years and older
Sex
All
01

Study summary

Objectives

  1. To observe whether sodium bicarbonate Ringer injections can reduce the incidence of postoperative complications in elderly patients undergoing abdominal surgery.
  2. To observe the effects of sodium bicarbonate Ringer injections on the internal environment, such as water, electrolytes, acid-base balance, and other physiological indexes, in the perioperative period of elderly patients undergoing abdominal surgery.

Research design:This study adopts a multicenter, prospective, randomized, controlled, pragmatic clinical trials (PCT) research design.

Sample size:5000 cases. Indication:The experimental group is the elderly patients undergoing abdominal surgery who were administered sodium bicarbonate Ringer injections intraoperatively; the control group is the elderly patients with abdominal surgery who were administered lactated Ringer's injections intraoperatively.

Observational index

Preoperative baseline data collection:

General patient information: basic information (age, height, and weight), preoperative diagnosis, past history, auxiliary examination results, etc.

Intraoperative data collection:

Perioperative vital signs information and arterial blood gas analysis results; The surgical method, operation time, and anaesthesia time; Intraoperative fluid management: The total amount of intraoperative fluids, blood transfusion volume, bleeding volume, urine volume, types and dosage of vasoactive drugs, diuretic dosage, sodium bicarbonate dosage.

Postoperative index:

Postoperative blood biochemical examination: liver function, renal function (urea nitrogen, creatinine), osmotic pressure, lactic acid, and blood sugar levels; Postoperative complications and treatment status Postoperative recovery: postoperative outcome, length of hospital stay, admission to ICU (duration of stay), postoperative eating time, out of bed activity time, gastrointestinal recovery time (exhaust), time for removal of various tubes (gastric tube, urinary tube, and drainage tube), etc.

The observation cut-off point is the patient's discharge. If the patient is still hospitalized 30 days after the operation, the observation will be terminated.

Research process

  1. Elderly abdominal surgery patients who meet the inclusion criteria will be enrolled and randomly divided into two groups according to the intraoperative application of extracellular fluid supplements. The experimental group is sodium bicarbonate Ringer injection group, and the control group is sodium lactate Ringer injection. Basic preoperative information of patients will be collected. The vital signs, fluid treatment, and surgical anaesthesia will be recorded during the operation, while the recovery and postoperative complications will be recorded during postoperative visits.
  2. The ability of sodium bicarbonate Ringer injections to reduce postoperative complications in elderly patients undergoing abdominal surgery will be observed.
  3. The effects of sodium bicarbonate Ringer injection on the internal environment, such as water, electrolytes, acid-base balance, and other physiological indexes in elderly patients undergoing abdominal surgery will be observed and compared.
  4. The safety and efficacy of sodium bicarbonate Ringer injection in elderly patients with abdominal diseases will be comprehensively assessed.
02

Conditions studied

  • Ringer Bicarbonate
  • Elderly Abdominal Surgery
  • Safety
  • Effectiveness
03

In context

Lead sponsor

Chinese PLA General Hospital is the lead sponsor of 558 studies on the registry; 202 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
65 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Inclusion criteria

  • (1) Patients need to be over 65 years of age, while there is no restriction on gender.
  • (2) Patients are planned to undergo upper abdominal surgery under general anaesthesia, with an expected operation time of >2 h, and the infusion volume is >1000ml.
  • (3) The patient agrees to participate in the clinical research and signs the informed consent.

Exclusion criteria

Exclusion Criteria:

  • (1) Emergency surgery
  • (2) Hypermagnesemia (defined as serum Mg2+ >1.25mmol/L)
  • (3) Patients who participated in other drug trials in the past 6 months
  • (4) Known allergic reactions to the test drug and/or its components
  • (5) Patients judged to lack the ability of providing informed consent
  • (6) Other situations considered unsuitable for enrollment by the researcher.
05

Study design

Phase
Phase 4
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Single (Participant)
Enrollment
5,000 participants (estimated)

Study arms

  • Experimental
    sodium bicarbonate Ringer injection

    Drug: sodium bicarbonate Ringer injection

  • Active comparator
    Ringer lactate solution

    Drug: Lactated Ringer's solution

Interventions

  • Drugsodium bicarbonate Ringer injection

    Used in surgery

  • DrugLactated Ringer's solution

    Used in surgery

06

What researchers measure

Primary outcomes

  1. Complication rate (including death)

    Complications include: bleeding, infection (incision infection, blood infection, urinary system infection), gastrointestinal complications (postoperative intestinal obstruction, anastomotic leakage), pulmonary complications (pulmonary infection, pulmonary embolism) ), cardiovascular complications (cardiac arrest, arrhythmia, heart failure, myocardial infarction), neurological complications (delirium, stroke), urinary system complications (renal insufficiency), etc. (refer to International Surgical Prognosis Study, ISOS ), and died during hospitalization.

    Time frame: 30days

07

Study locations

No study locations are listed for this record.

08

References and documents

Individual participant data

Plan to share: Undecided

No publications or documents are linked to this record.

09

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on Oct 22, 2020, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT04596956
Lead sponsor
Chinese PLA General Hospital
Responsible party
Weidong Mi (Director of the Center for Anesthesia, Chinese PLA General Hospital) — Principal investigator
First posted
Oct 22, 2020
Start date
Oct 2020 (estimated)
Primary completion
Aug 2025 (estimated)
Completion
Dec 2025 (estimated)
Last update
Oct 22, 2020

Study contacts

Wenzhu Shi
Contact
shiwenzhu@163.com
+86-15110199887

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Oct 2020. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion